Bristol Myers Squibb Company (NYSE:BMY) Given Consensus Recommendation of "Hold" by Brokerages

Key Points

• Bristol Myers Squibb has an average analyst rating of "Hold" from 19 firms (1 sell, 10 hold, 8 buy) with a 12‑month consensus target price of $61.31.
• The company missed Q4 EPS expectations, reporting $1.26 versus a $1.65 consensus while posting revenue of $12.50 billion (vs. $12.24B est.), and it set FY‑2026 guidance of 6.050–6.350 EPS (analysts expect ~6.28).
• BMS declared a quarterly dividend of $0.63 per share (annualized $2.52), implying a 4.4% yield with an ex‑dividend date of April 2 and a dividend payout ratio of about 73%.

Shares of Bristol Myers Squibb Company (NYSE:BMY - Get Free Report) have received an average rating of "Hold" from the nineteen research firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and eight have assigned a buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $61.3125.

Several analysts have recently weighed in on BMY shares. Morgan Stanley reiterated an "underweight" rating and set a $40.00 target price on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Guggenheim reiterated a "buy" rating and set a $72.00 target price on shares of Bristol Myers Squibb in a research report on Wednesday, April 8th. Citigroup lifted their price target on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the company a "neutral" rating in a report on Friday, February 6th. Wall Street Zen raised shares of Bristol Myers Squibb from a "buy" rating to a "strong-buy" rating in a report on Sunday, April 19th. Finally, Cantor Fitzgerald lifted their price target on shares of Bristol Myers Squibb from $45.00 to $54.00 and gave the company a "neutral" rating in a report on Wednesday, April 8th.

Bristol Myers Squibb Price Performance

Shares of Bristol Myers Squibb stock opened at $57.86 on Tuesday. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26. The firm's 50-day simple moving average is $59.63 and its 200-day simple moving average is $54.31. Bristol Myers Squibb has a twelve month low of $42.52 and a twelve month high of $62.89. The firm has a market cap of $118.13 billion, a P/E ratio of 16.77, a price-to-earnings-growth ratio of 0.17 and a beta of 0.27.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The business had revenue of $12.50 billion for the quarter, compared to analyst estimates of $12.24 billion. During the same quarter last year, the firm posted $1.67 earnings per share. Bristol Myers Squibb's revenue was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, research analysts expect that Bristol Myers Squibb will post 6.28 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Investors of record on Thursday, April 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.4%. The ex-dividend date of this dividend is Thursday, April 2nd. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 73.04%.

Insider Transactions at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 30,000 shares of Bristol Myers Squibb stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the transaction, the executive vice president directly owned 159,248 shares of the company's stock, valued at $9,820,824.16. This trade represents a 15.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.05% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Bristol Myers Squibb

Institutional investors have recently added to or reduced their stakes in the company. Northwestern Mutual Investment Management Company LLC grew its position in Bristol Myers Squibb by 0.3% in the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 65,046 shares of the biopharmaceutical company's stock valued at $3,509,000 after purchasing an additional 172 shares during the period. KCM Investment Advisors LLC boosted its holdings in Bristol Myers Squibb by 0.8% during the 4th quarter. KCM Investment Advisors LLC now owns 20,871 shares of the biopharmaceutical company's stock worth $1,126,000 after acquiring an additional 174 shares during the last quarter. Investment Research Partners LLC boosted its holdings in Bristol Myers Squibb by 1.4% during the 4th quarter. Investment Research Partners LLC now owns 13,134 shares of the biopharmaceutical company's stock worth $708,000 after acquiring an additional 179 shares during the last quarter. ESG Planning DBA Harper Investing boosted its holdings in Bristol Myers Squibb by 1.3% during the 4th quarter. ESG Planning DBA Harper Investing now owns 13,811 shares of the biopharmaceutical company's stock worth $745,000 after acquiring an additional 180 shares during the last quarter. Finally, REAP Financial Group LLC boosted its holdings in Bristol Myers Squibb by 26.1% during the 4th quarter. REAP Financial Group LLC now owns 879 shares of the biopharmaceutical company's stock worth $47,000 after acquiring an additional 182 shares during the last quarter. 76.41% of the stock is owned by institutional investors.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.